Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (301-310 of 420) with videos related to

Pageof 42
Sort By:
Diagnostic Microbiology and Infectious Disease|March 24, 2009
In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogensRonald N Jones, Jan M Bell, Helio S Sader, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 30, 2019
<i>In Vitro</i> Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> (2014-2015) in the United StatesMichael A Pfaller, Helio S Sader, Paul R Rhomberg, et al.
Antimicrobial Agents and Chemotherapy|September 9, 2020
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers WorldwideHelio S Sader, Leonard R Duncan, S J Ryan Arends, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2016
Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC ResultsRodrigo E Mendes, David J Farrell, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy|March 26, 2016
Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility ratesRodrigo E Mendes, Patricia A Hogan, Ronald N Jones, et al.
Journal of Global Antimicrobial Resistance|July 24, 2017
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014)Leonard R Duncan, Helio S Sader, Jennifer I Smart, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2014
Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing methodRodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Antibiotics (Basel, Switzerland)|November 27, 2025
Antimicrobial Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations Tested Against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019-2023)Helio S Sader, Marisa L Winkler, Krisztina M Papp-Wallace, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 15, 2005
Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin AmericaAna Cristina Gales, Michael A Pfaller, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004)Thomas R Fritsche, Helio S Sader, Matthew G Stilwell, et al.
Pageof 42

Showing results (301-310 of 420) with videos related to

Sort By:
Pageof 42
Diagnostic Microbiology and Infectious Disease|March 24, 2009
In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogensRonald N Jones, Jan M Bell, Helio S Sader, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 30, 2019
<i>In Vitro</i> Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> (2014-2015) in the United StatesMichael A Pfaller, Helio S Sader, Paul R Rhomberg, et al.
Antimicrobial Agents and Chemotherapy|September 9, 2020
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers WorldwideHelio S Sader, Leonard R Duncan, S J Ryan Arends, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2016
Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC ResultsRodrigo E Mendes, David J Farrell, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy|March 26, 2016
Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility ratesRodrigo E Mendes, Patricia A Hogan, Ronald N Jones, et al.
Journal of Global Antimicrobial Resistance|July 24, 2017
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014)Leonard R Duncan, Helio S Sader, Jennifer I Smart, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2014
Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing methodRodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Antibiotics (Basel, Switzerland)|November 27, 2025
Antimicrobial Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations Tested Against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019-2023)Helio S Sader, Marisa L Winkler, Krisztina M Papp-Wallace, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|January 15, 2005
Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin AmericaAna Cristina Gales, Michael A Pfaller, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004)Thomas R Fritsche, Helio S Sader, Matthew G Stilwell, et al.
Pageof 42